Drug Insight

VEGF as a therapeutic target for breast cancer

Bryan Schneider, George W. Sledge

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Angiogenesis is implicated in the pathogenesis of malignancy and metastasis. Inhibition of angiogenesis has demonstrated clinically significant improvements in outcomes in a variety of malignancies, including breast cancer. The humanized monoclonal antibody against VEGF, bevacizumab, is the clinically most mature of the antiangiogenic agents and has recently been shown to improve outcome when combined with chemotherapy in the first-line metastatic setting of breast cancer. A variety of other antiangiogenic agents are currently under investigation, including drugs that inhibit the VEGF receptor 2, the cognate receptor for VEGF found on endothelial cells. The combination of antiangiogenic drugs with one another and with other biologic agents is also being explored in an attempt to improve efficacy and to overcome the drug resistance seen with the initial studies of antiangiogenic agents. This Review will focus on the current state of therapeutics designed to inhibit this angiogenic process in breast cancer.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalNature Clinical Practice Oncology
Volume4
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor
Breast Neoplasms
Pharmaceutical Preparations
Antibodies, Monoclonal, Humanized
Biological Factors
Drug Combinations
Drug Resistance
Neoplasms
Therapeutics
Endothelial Cells
Neoplasm Metastasis
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Drug Insight : VEGF as a therapeutic target for breast cancer. / Schneider, Bryan; Sledge, George W.

In: Nature Clinical Practice Oncology, Vol. 4, No. 3, 03.2007, p. 181-189.

Research output: Contribution to journalArticle

@article{6ffbd531bd9f42bb8c01dea94f09f851,
title = "Drug Insight: VEGF as a therapeutic target for breast cancer",
abstract = "Angiogenesis is implicated in the pathogenesis of malignancy and metastasis. Inhibition of angiogenesis has demonstrated clinically significant improvements in outcomes in a variety of malignancies, including breast cancer. The humanized monoclonal antibody against VEGF, bevacizumab, is the clinically most mature of the antiangiogenic agents and has recently been shown to improve outcome when combined with chemotherapy in the first-line metastatic setting of breast cancer. A variety of other antiangiogenic agents are currently under investigation, including drugs that inhibit the VEGF receptor 2, the cognate receptor for VEGF found on endothelial cells. The combination of antiangiogenic drugs with one another and with other biologic agents is also being explored in an attempt to improve efficacy and to overcome the drug resistance seen with the initial studies of antiangiogenic agents. This Review will focus on the current state of therapeutics designed to inhibit this angiogenic process in breast cancer.",
author = "Bryan Schneider and Sledge, {George W.}",
year = "2007",
month = "3",
doi = "10.1038/ncponc0740",
language = "English",
volume = "4",
pages = "181--189",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Drug Insight

T2 - VEGF as a therapeutic target for breast cancer

AU - Schneider, Bryan

AU - Sledge, George W.

PY - 2007/3

Y1 - 2007/3

N2 - Angiogenesis is implicated in the pathogenesis of malignancy and metastasis. Inhibition of angiogenesis has demonstrated clinically significant improvements in outcomes in a variety of malignancies, including breast cancer. The humanized monoclonal antibody against VEGF, bevacizumab, is the clinically most mature of the antiangiogenic agents and has recently been shown to improve outcome when combined with chemotherapy in the first-line metastatic setting of breast cancer. A variety of other antiangiogenic agents are currently under investigation, including drugs that inhibit the VEGF receptor 2, the cognate receptor for VEGF found on endothelial cells. The combination of antiangiogenic drugs with one another and with other biologic agents is also being explored in an attempt to improve efficacy and to overcome the drug resistance seen with the initial studies of antiangiogenic agents. This Review will focus on the current state of therapeutics designed to inhibit this angiogenic process in breast cancer.

AB - Angiogenesis is implicated in the pathogenesis of malignancy and metastasis. Inhibition of angiogenesis has demonstrated clinically significant improvements in outcomes in a variety of malignancies, including breast cancer. The humanized monoclonal antibody against VEGF, bevacizumab, is the clinically most mature of the antiangiogenic agents and has recently been shown to improve outcome when combined with chemotherapy in the first-line metastatic setting of breast cancer. A variety of other antiangiogenic agents are currently under investigation, including drugs that inhibit the VEGF receptor 2, the cognate receptor for VEGF found on endothelial cells. The combination of antiangiogenic drugs with one another and with other biologic agents is also being explored in an attempt to improve efficacy and to overcome the drug resistance seen with the initial studies of antiangiogenic agents. This Review will focus on the current state of therapeutics designed to inhibit this angiogenic process in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=33847643631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847643631&partnerID=8YFLogxK

U2 - 10.1038/ncponc0740

DO - 10.1038/ncponc0740

M3 - Article

VL - 4

SP - 181

EP - 189

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 3

ER -